{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T15:39:30Z","timestamp":1776613170895,"version":"3.51.2"},"reference-count":56,"publisher":"Elsevier BV","issue":"3-5","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.jsbmb.2012.01.001","type":"journal-article","created":{"date-parts":[[2012,1,13]],"date-time":"2012-01-13T09:01:06Z","timestamp":1326445266000},"page":"115-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys"],"prefix":"10.1016","volume":"129","author":[{"given":"Masuo","family":"Yamaoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takenori","family":"Hitaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Asahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Kusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2012.01.001_bib0005","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0010","first-page":"293","article-title":"Studies on prostate cancer. I. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1634\/theoncologist.5-1-36","article-title":"Management of advanced prostate cancer","volume":"5","author":"Auclerc","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0020","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","article-title":"Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)","volume":"22","author":"Small","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0025","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0030","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6601127","article-title":"Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer","volume":"89","author":"Edwards","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0002-9440(10)63112-4","article-title":"Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance","volume":"164","author":"Holzbeierlein","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Chen","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0045","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/1535-7163.MCT-08-0823","article-title":"Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2","volume":"8","author":"Feng","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0050","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0006-291X(05)80067-1","article-title":"A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens","volume":"173","author":"Veldscholte","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0055","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/0960-0760(90)90431-J","article-title":"Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion","volume":"37","author":"Schuurmans","year":"1990","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0060","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1210\/jcem.80.12.8530589","article-title":"Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol","volume":"80","author":"Elo","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0065","first-page":"149","article-title":"Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome","volume":"63","author":"Hara","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0070","doi-asserted-by":"crossref","first-page":"9611","DOI":"10.1158\/0008-5472.CAN-05-0817","article-title":"Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient","volume":"65","author":"Yoshida","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0075","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/mend.11.4.9906","article-title":"Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells","volume":"11","author":"Tan","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/humu.21138","article-title":"Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line","volume":"31","author":"Marcias","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0085","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","article-title":"Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance","volume":"68","author":"Dehm","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"Hu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0095","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","article-title":"A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth","volume":"69","author":"Guo","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0100","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0889-8529(08)70021-5","article-title":"The genetics pathophysiology, and management of human deficiencies of P450c17","volume":"30","author":"Auchus","year":"2001","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0110","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1172\/JCI110903","article-title":"Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes","volume":"71","author":"Loose","year":"1983","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0115","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0120","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0125","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1016\/j.bmc.2011.08.066","article-title":"Discovery of orteronel (TAK-700) a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer","volume":"19","author":"Kaku","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-2004-861548","article-title":"Variations in adrenal androgen production among (nonhuman) primates","volume":"22","author":"Conley","year":"2004","journal-title":"Semin. Reprod. Med."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11154-008-9099-8","article-title":"Nonhuman primates as models for human adrenal androgen production: function and dysfunction","volume":"10","author":"Abbott","year":"2009","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0140","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1046\/j.1432-1033.2002.03268.x","article-title":"Baboon cytochrome P450 17\u03b1-hydroxylase\/17,20-lyase (CYP17): characterization of the adrenal microsomeal and cloned enzymes","volume":"269","author":"Swart","year":"2002","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0145","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1210\/en.2002-220456","article-title":"Molecular evolution of adrenarche: structural and functional analysis of P450c17 from 4 primate species","volume":"143","author":"Arlt","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0150","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1021\/jm00013a022","article-title":"Novel steroidal inhibitors of human cytochrome p45017\u03b1 (l7\u03b1-hydroxylase-Cl7,20-lyase): potential agents for the treatment of prostatic cancer","volume":"38","author":"Potter","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0155","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1172\/JCI110132","article-title":"The developmental changes in plasma adrenal androgens during infancy and adrenarche are associated with changing activities of adrenal microsomal 17-hydroxylase and 17,20-desmolase","volume":"67","author":"Schiebinger","year":"1981","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0160","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0039-128X(87)90090-0","article-title":"Adrenal 11-hydroxylase activity in a hypercortisolemic New World primate: adaptive intra-adrenal changes","volume":"49","author":"Albertson","year":"1987","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0165","doi-asserted-by":"crossref","first-page":"19681","DOI":"10.1016\/S0021-9258(19)36570-6","article-title":"Expression and purification of functional human 17 alpha-hydroxylase\/17,20-lyase (P450c17) in Escherichia coli. Use of this system for study of a novel form of combined 17 alpha-hydroxylase\/17,20-lyase deficiency","volume":"268","author":"Imai","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0170","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1210\/jcem-40-5-850","article-title":"24-Hour secretory pattern of dehydroisoandrosterone and dehydroisoandrosterone sulphate","volume":"40","author":"Rosenfeld","year":"1975","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0175","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1210\/jcem-32-2-266","article-title":"Characterization of the normal temporal pattern of plasma corticosteroid levels","volume":"32","author":"Krieger","year":"1971","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0180","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1210\/jcem-36-6-1058","article-title":"ACTH and cortisol secretory patterns in man","volume":"36","author":"Gallagher","year":"1973","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0185","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1210\/jcem-32-6-846","article-title":"Diurnal variations in the levels of plasma and urinary androgens","volume":"32","author":"Okamoto","year":"1971","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0190","first-page":"63","article-title":"Feedback regulation of gonadotrophins in the male","volume":"10","author":"Davidson","year":"1973","journal-title":"Adv. Biosci."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0195","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/bjc.1989.336","article-title":"A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen Casodex (ICI 176,334)","volume":"60","author":"Freeman","year":"1989","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0200","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/07435809609043744","article-title":"Forskolin treatment directs steroid production towards the androgen pathway in the NCI-H295R adrenocortical tumour cell line","volume":"22","author":"Cobb","year":"1996","journal-title":"Endocr. Res."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0205","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1016\/S0021-9258(19)69538-4","article-title":"Microsomal cytochrome P-450 from neonatal pig testis. Purification and properties of A C21 steroid side-chain cleavage system (17 alpha-hydroxylase-C17,20 lyase)","volume":"256","author":"Nakajin","year":"1981","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0210","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1081\/ERC-120016821","article-title":"Towards a unifying mechanism for CYP17 mutations that cause isolated 17,20-lyase deficiency","volume":"28","author":"Auchus","year":"2002","journal-title":"Endocr. Res."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0215","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1074\/jbc.273.6.3158","article-title":"Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer","volume":"273","author":"Auchus","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0220","first-page":"3382","volume":"84","author":"Mapes","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0225","series-title":"Proceedings of the 101st Annual Meeting of the American Association for Cancer Research","article-title":"TAK-700: an inhibitor of 17,20-lyase","author":"Yamaoka","year":"2010"},{"issue":"15s","key":"10.1016\/j.jsbmb.2012.01.001_bib0230","article-title":"Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I\/II, open-label study","volume":"28","author":"Dreicer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0235","first-page":"180","article-title":"Abiraterone acetate: the novel application of a CYP450c17 inhibitor to the treatment of both prostate and breast cancer","volume":"19","author":"Folkerd","year":"2009","journal-title":"Endocr. Abstr."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0240","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0245","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0250","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0255","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/pros.20269","article-title":"Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression","volume":"67","author":"Fuse","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0260","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","article-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer","volume":"28","author":"Danila","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0265","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","article-title":"Significant sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate","volume":"28","author":"Reid","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0270","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.bjc.6604904","article-title":"CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer","volume":"100","author":"Ang","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0275","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-08-4531","article-title":"Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2012.01.001_bib0280","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1517\/13543781003639427","article-title":"Abiraterone acetate for castration resistant prostate cancer","volume":"19","author":"Shah","year":"2010","journal-title":"Expert Opin. Invest. Drugs"}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076012000118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076012000118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:38:30Z","timestamp":1760744310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076012000118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":56,"journal-issue":{"issue":"3-5","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0960076012000118"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2012.01.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13993963.15450064","asserted-by":"object"}]},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2012.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}